Tradestie Institutional Equity Comparison Engine
CONX vs AAPG โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AAPG Overall Edge
AAPG Captures Institutional Edge (3โ0 Pillars ยท 9โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ascentage Pharma Group International American Depository Shares (AAPG) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, CONX trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus AAPG at 9.4x Forward P/E and -219.5% operating margin (+29.3% YoY). In options structure, CONX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AAPG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
AAPG
CONX N/M vs AAPG 9.4x Fwd P/E
Growth & Margin Winner
AAPG
Op Margin N/A vs -219.5% ยท YoY N/A vs +29.3%
Momentum & Technical Winner
AAPG
1Y -89.0% vs -60.2% ยท 52W Pos 0% vs 0%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CONX
US Equity
CONX
Institutional Equity
$2.66
-11.75% 1D
Market Cap
N/A
1M Return
-54.66%
1Y Return
-88.97%
Forward P/E
N/M
Unified AI Score
42.0 / 100
HOLD
Tech 25.0
Fund 54.0
Flow 50.0
Mom 55.0
AAPG
NASDAQ
Ascentage Pharma Group International American Depository Shares
Pharmaceutical Preparations
$13.29
-9.1% 1D
Market Cap
$1.4B
1M Return
-13.53%
1Y Return
-60.21%
Forward P/E
9.4x
Unified AI Score
49.7 / 100
HOLD
Tech 58.0
Fund 57.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CONX -88.97%
AAPG -60.21%
Spread: +30.24 pp (AAPG Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CONX TTM Op. Margin: N/A
AAPG TTM Op. Margin: -219.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CONX vs AAPG. Trailing 12-month operating profitability (CONX N/A vs AAPG -219.5%) and valuation multiples (CONX N/M vs AAPG 9.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CONX | AAPG | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $1.4B | Larger Scale | AAPG |
| Trailing P/E Ratio Valuation | N/M | 9.4x | Lower Multiple | AAPG |
| Forward P/E Ratio Valuation | N/M | 9.4x | Lower Multiple | AAPG |
| Revenue Growth (YoY) Growth | N/A | +29.3% | Higher Growth | AAPG |
| Operating Margin (TTM) Profitability | N/A | -219.5% | Higher Margin | AAPG |
| Net Profit Margin Profitability | N/A | -228.5% | Higher Margin | AAPG |
| Return on Equity (ROE) Capital Efficiency | N/A | -236.6% | Higher ROE | AAPG |
| 52-Week Range Position Momentum | 0% ($3โ$28) | 0% ($13โ$34) | Stronger Trend | Tie |
| Beta / 30D Volatility Risk Regime | 4.88ฮฒ ยท 135% Vol | 1.32ฮฒ ยท 70% Vol | Lower Realized Risk | AAPG |
| Unified Institutional Score Composite Signal | 42.0 / 100 (HOLD) | 49.7 / 100 (HOLD) | Higher Composite | AAPG |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CONX vs AAPG Buy Guide
CONX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
AAPG
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CONX nor AAPG registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.